Immix Biopharma Inc

NASDAQ IMMX

Download Data

Immix Biopharma Inc Net Working Capital to Total Assets Ratio 3 year CAGR for the quarter ending March 31, 2024

Immix Biopharma Inc Net Working Capital to Total Assets Ratio 3 year CAGR is NA for the quarter ending March 31, 2024. The net working capital to total assets ratio measures the proportion of a company's net working capital (current assets minus current liabilities) to its total assets. It is calculated by dividing the net working capital by the total assets. This ratio indicates the percentage of a company's total assets that are financed by its net working capital. A higher ratio suggests a greater reliance on working capital to fund the company's operations and indicates a potential liquidity cushion. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Immix Biopharma Inc Net Working Capital to Total Assets Ratio for the quarter ending March 31, 2023 was 0.88, a -10.85% change year over year.
  • Immix Biopharma Inc Net Working Capital to Total Assets Ratio for the quarter ending March 31, 2022 was 0.98.
NASDAQ: IMMX

Immix Biopharma Inc

CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date Dec. 16, 2021
Location United States
Headquarters 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

AVRO

AVROBIO Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email